Metformin Use in Patients with Reduced Kidney Function

GFR Thresholds and Recommendations

• For patients with eGFR 30-44 mL/min/1.73m², review therapy and consider dose reduction, according to the American Journal of Kidney Diseases guidelines 1
• For patients with eGFR 45-59 mL/min/1.73m², metformin can be continued at standard doses, as recommended by the American Journal of Kidney Diseases 1
• For patients with eGFR ≥60 mL/min/1.73m², standard dosing and monitoring can be maintained, based on the American Journal of Kidney Diseases guidelines 1

Special Considerations

• Temporarily discontinue metformin during acute illness that may affect kidney function, as suggested by the American Journal of Kidney Diseases 1
• Discontinue metformin at the time of, or prior to, iodinated contrast imaging procedures in patients with history of liver disease, alcoholism, or heart failure, according to the American Journal of Kidney Diseases 2

Benefits vs. Risks

• Population studies show that metformin use in patients with eGFR 45-60 mL/min/1.73m² is associated with reduced mortality compared to other glucose-lowering therapies, as reported by the American Journal of Kidney Diseases 3
• Metformin offers cardiovascular benefits, effective glucose control, and weight neutrality that should be considered when evaluating its use in patients with reduced renal function, according to the American Journal of Kidney Diseases 3

Alternative Options When Metformin is Contraindicated

• DPP-4 inhibitors with appropriate renal dose adjustment have minimal risk of hypoglycemia, as stated by the American Journal of Kidney Diseases 3
• Avoid first-generation sulfonylureas in patients with CKD as they rely on renal elimination, based on the American Journal of Kidney Diseases guidelines 2

Common Pitfalls to Avoid

• Using serum creatinine alone rather than eGFR to guide metformin use can lead to inappropriate discontinuation, especially in elderly or small-statured patients, as warned by the American Journal of Kidney Diseases 1
• Failing to adjust metformin dose proportionally to the decline in GFR increases risk of accumulation, according to the American Journal of Kidney Diseases guidelines 1

Metformin Use in Patients with Reduced Kidney Function

Introduction to Metformin Therapy

• The American College of Cardiology and other guideline societies recommend metformin for patients with type 2 diabetes and chronic kidney disease (CKD) with an eGFR ≥30 mL/min/1.73 m² 4
• Metformin can be safely continued in patients with an eGFR of 51 mL/min/1.73 m², but requires more frequent monitoring of kidney function and consideration of dose adjustment 4, 5

Monitoring and Dose Adjustment

• Increase the frequency of eGFR monitoring since the patient's eGFR is <60 mL/min/1.73 m² 4
• Monitor kidney function at least every 3-6 months 4, 6
• Monitor for vitamin B12 deficiency, especially if the patient has been on metformin for more than 4 years 4
• With an eGFR of 51 mL/min/1.73 m², the standard dose may be continued in most patients 4
• Consider dose reduction if the patient has other risk factors for lactic acidosis such as risk of volume depletion 5

Safety and Efficacy

• The risk of metformin-associated lactic acidosis is very low in patients with eGFR >45 mL/min/1.73 m² 5
• Population studies show that metformin use in patients with eGFR 45-60 mL/min/1.73 m² is associated with reduced mortality compared to other glucose-lowering therapies 5, 7

Discontinuation and Alternative Options

• If the patient's eGFR falls below 45 mL/min/1.73 m², the dose should be halved 4
• If the eGFR falls below 30 mL/min/1.73 m², metformin must be discontinued 4
• If metformin needs to be discontinued due to worsening kidney function, consider GLP-1 receptor agonists as they have documented cardiovascular benefits 4
• DPP-4 inhibitors with appropriate renal dose adjustment may be alternatives with minimal risk of hypoglycemia 7, 8

Metformin Discontinuation in Severe Renal Impairment

Introduction to Metformin Contraindications

• The National Kidney Foundation's KDOQI guidelines recommend discontinuation of metformin at GFR <30 mL/min/1.73 m² (Stage 4-5 CKD) 9
• The American College of Physicians and other major guidelines unanimously recommend discontinuation when GFR falls below 30 mL/min/1.73 m², with metformin being renally eliminated and at a GFR of 7, drug accumulation to toxic levels is inevitable 10

Lactic Acidosis Risk and Prevention

• While lactic acidosis is rare at higher GFR levels (>30), the risk becomes substantial and potentially fatal when renal clearance is severely impaired, with a high mortality rate associated with metformin-induced lactic acidosis 10, 11

Evidence-Based Recommendations

• The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend discontinuation at GFR <30 mL/min/1.73 m² (Stage 4-5 CKD), with the 2021 Lancet guidelines stating metformin should be discontinued if eGFR is less than 30 mL/min/1.73 m² 9, 11

Alternative Management Strategies

• DPP-4 inhibitors with appropriate renal dose adjustments are safer alternatives for diabetes management in severe renal impairment, though linagliptin requires no dose adjustment, and insulin therapy becomes the primary option for glycemic control in Stage 5 CKD 10

Alternative Add-On Therapy to Metformin in High Creatinine

Introduction to Alternative Therapies

• The American Journal of Kidney Diseases recommends that when metformin must be discontinued or dose-reduced due to elevated creatinine, a GLP-1 receptor agonist (long-acting formulation) should be added as the preferred alternative, followed by DPP-4 inhibitors with renal dose adjustment if GLP-1 RA is not tolerated or affordable 12

Determining Metformin Status and Alternative Therapies

• For patients with eGFR ≥60 mL/min/1.73 m², the Kidney International guideline suggests continuing metformin at standard doses 12
• The Kidney International guideline recommends that GLP-1 receptor agonists are the preferred add-on or replacement therapy when metformin cannot be used at full dose or must be discontinued 12
• Dulaglutide, a GLP-1 receptor agonist, can be used at a dose of 0.75-1.5 mg once weekly, with no dose adjustment needed, and can be used down to eGFR >15 mL/min/1.73 m² 12
• Prioritize GLP-1 receptor agonists with documented cardiovascular benefits, such as dulaglutide, liraglutide, and semaglutide 12

Second-Line and Third-Line Alternative Therapies

• The American Journal of Kidney Diseases recommends that if cost is the primary barrier and neither GLP-1 RA nor DPP-4 inhibitors are accessible, glipizide is the only acceptable sulfonylurea in renal impairment 13, 14
• Glipizide has no active metabolites, does not accumulate in CKD, and should be started at a low dose and titrated cautiously 13, 14
• The American Journal of Kidney Diseases guideline suggests that pioglitazone can be used in CKD as it is hepatically metabolized, but fluid retention limits its use 13

Insulin Therapy and Monitoring Requirements

• For patients with eGFR <30 mL/min/1.73 m², the American Journal of Kidney Diseases recommends that insulin becomes the primary option for glycemic control when oral agents are insufficient 13, 14
• Insulin half-life is prolonged due to reduced renal degradation, and patients with mean creatinine 2.2 mg/dL have a 5-fold increased risk of severe hypoglycemia 13, 14
• The American Journal of Kidney Diseases guideline suggests reducing insulin doses by 25-50% as eGFR declines below 30 mL/min/1.73 m² 13, 14

Metformin Management in Chronic Kidney Disease

Introduction to Metformin Use in CKD

• The American Journal of Kidney Diseases recommends discontinuing metformin completely when the GFR falls below 30 mL/min/1.73 m² 15
• The American Journal of Kidney Diseases also notes that the risk of metformin-associated lactic acidosis remains very low above eGFR 30 mL/min/1.73 m², with metformin levels only 2-fold higher than normal kidney function at this GFR range 15

Temporary Discontinuation of Metformin

• Diabetes Care suggests temporarily stopping metformin during acute illness that may compromise renal function, such as sepsis, fever, severe diarrhea, vomiting, dehydration, and during hospitalizations where acute kidney injury risk is elevated 16
• Diabetes Care also recommends temporarily discontinuing metformin during iodinated contrast procedures in patients with a history of liver disease, alcoholism, or heart failure, although this is not exclusively cited 16

Metformin Use in Patients with Chronic Kidney Disease

Introduction to Metformin Use

• The American Diabetes Association recommends that metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m², and this is the absolute lowest threshold for metformin use, in patients with chronic kidney disease 17

FDA-Approved GFR Thresholds for Metformin Use

• The FDA revised guidance in 2016 establishes clear eGFR-based thresholds that supersede older creatinine-based restrictions, for patients with chronic kidney disease, and recommends to continue current metformin dose but reassess benefit-risk balance in patients with eGFR 45-59 mL/min/1.73 m² 17
• The FDA revised guidance in 2016 establishes clear eGFR-based thresholds that supersede older creatinine-based restrictions, for patients with chronic kidney disease, and recommends not to initiate metformin therapy in patients with eGFR 45-59 mL/min/1.73 m² 17
• The FDA revised guidance in 2016 establishes clear eGFR-based thresholds that supersede older creatinine-based restrictions, for patients with chronic kidney disease, and recommends not to initiate metformin therapy in patients with eGFR 30-44 mL/min/1.73 m² 17
• The FDA revised guidance in 2016 establishes clear eGFR-based thresholds that supersede older creatinine-based restrictions, for patients with chronic kidney disease, and recommends to carefully reassess benefit-risk balance in patients with eGFR 30-44 mL/min/1.73 m² 17
• The FDA revised guidance in 2016 establishes clear eGFR-based thresholds that supersede older creatinine-based restrictions, for patients with chronic kidney disease, and recommends an absolute contraindication—discontinue metformin immediately in patients with eGFR <30 mL/min/1.73 m² 17

Critical Safety Considerations for Metformin Use

• The American College of Cardiology recommends to hold metformin at the time of or before contrast imaging in patients with eGFR 30-60 mL/min/1.73 m², history of liver disease, alcoholism, or heart failure, or intra-arterial contrast administration, and to re-evaluate eGFR 48 hours post-procedure before restarting 17

Metformin and Acute Kidney Injury

Introduction to Metformin and AKI

• Metformin itself does not cause or worsen acute kidney injury—rather, AKI impairs metformin clearance, leading to drug accumulation and the life-threatening complication of lactic acidosis, as stated by the Kidney International guidelines 18, 19
• The American Diabetes Association and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines provide high-quality evidence that metformin-associated lactic acidosis (MALA) occurs when acute kidney injury contributes to reduced metformin clearance, rather than metformin causing the injury 18, 19

Metformin Clearance and Accumulation

• Metformin is excreted unchanged in urine, making it entirely dependent on kidney function for elimination, according to the Kidney International guidelines 18, 19
• Most episodes of MALA occur concurrent with acute illness, where AKI contributes to reduced metformin clearance rather than metformin causing the kidney injury, as reported in the Kidney International journal 18, 19

Safe Creatinine Levels for Metformin Use

Introduction to Metformin Use Guidelines

• The American College of Cardiology and other guideline societies recommend using eGFR—not serum creatinine alone—to guide metformin prescribing decisions, as metformin is safe when eGFR is ≥30 mL/min/1.73 m² 20

eGFR-Based Prescribing Algorithm

• For patients with eGFR ≥60 mL/min/1.73 m², the standard metformin dosing can be continued (up to 2000-2550 mg daily) and kidney function should be monitored at least annually 20
• For patients with eGFR 45-59 mL/min/1.73 m², the current metformin dose can be continued in most patients, with increased monitoring frequency to every 3-6 months 20
• For patients with eGFR 30-44 mL/min/1.73 m², the metformin dose should be reduced by 50% (halved) and kidney function should be monitored every 3-6 months 20
• For patients with eGFR <30 mL/min/1.73 m², metformin should be discontinued immediately due to the risk of toxic levels and substantially increased mortality risk 20

Monitoring and Alternative Therapies

• Vitamin B12 levels should be monitored in patients on metformin for more than 4 years 20
• If metformin must be discontinued, first-line alternative therapies include long-acting GLP-1 receptor agonists with documented cardiovascular benefits (dulaglutide, liraglutide, semaglutide) 20

Management of Metformin in Acute Kidney Injury

Introduction to Metformin Management

• The American Journal of Kidney Diseases recommends that metformin should not be restarted until eGFR has recovered to ≥30 mL/min/1.73 m², among other criteria 21

Dosing Considerations

• For patients with eGFR ≥60 mL/min/1.73 m², standard dosing of metformin may be resumed, with annual eGFR monitoring 21
• For patients with eGFR 30-44 mL/min/1.73 m², the dose of metformin should be reduced to a maximum of 1000 mg daily, with eGFR monitoring every 3-6 months 21
• For patients with eGFR <30 mL/min/1.73 m², metformin is contraindicated and should not be restarted 21

Metformin Initiation and Use in Patients with Impaired Kidney Function

Introduction to Metformin Use

• The American Journal of Kidney Diseases guidelines state that metformin can be continued at standard doses in patients with eGFR 45-59 mL/min/1.73 m², with population studies demonstrating reduced mortality compared to alternative therapies 22
• In clinical practice, most experts would initiate metformin at eGFR 58 mL/min/1.73 m² given the substantial cardiovascular and mortality benefits, particularly in overweight patients 22

Monitoring and Dosing

• Measure serum creatinine with any dose increase, as recommended by the Journal of the American Geriatrics Society (JAGS) 23, 24

Evidence Supporting Metformin Use

• In the Swedish National Diabetes Register, patients with eGFR 45-60 mL/min/1.73 m² on metformin had reduced mortality risk compared to those on other glucose-lowering therapies 22
• Metformin use is associated with reduced 2-year mortality in patients with eGFR 30-60 mL/min/1.73 m² 22
• Metformin demonstrates cardiovascular benefit in overweight patients, with negligible hypoglycemia risk and no weight gain 22

Alternative Agents

• If metformin becomes contraindicated, first-line alternatives include GLP-1 receptor agonists (dulaglutide, liraglutide, semaglutide) and DPP-4 inhibitors with renal dose adjustment (e.g., sitagliptin 50 mg daily at eGFR 45-59 mL/min/1.73 m²) 22

Metformin Management Based on GFR

GFR-Based Dosing Adjustments

• For patients with eGFR ≥60 mL/min/1.73 m², no dose adjustment is required, and kidney function should be monitored at least annually, according to Endocrine Reviews 25
• For patients with eGFR 30-44 mL/min/1.73 m², the metformin dose should be reduced by 50% (maximum 1000 mg daily), and kidney function should be monitored every 3-6 months, as recommended by Endocrine Reviews 25
• For patients with eGFR <30 mL/min/1.73 m², metformin should be discontinued immediately, as stated in Endocrine Reviews 25

Alternative Therapies

• When metformin is contraindicated at eGFR <30 mL/min/1.73 m², first-line alternatives include GLP-1 receptor agonists (dulaglutide, liraglutide, semaglutide) with documented cardiovascular benefits, as suggested by Endocrine Reviews 25
• Second-line alternatives include DPP-4 inhibitors with renal dose adjustment (sitagliptin 25 mg daily at eGFR <30, linagliptin requires no adjustment), as recommended by Endocrine Reviews 25
• Insulin therapy becomes the primary option for glycemic control in Stage 5 CKD, with a reduced total daily insulin dose by 25-50% as eGFR declines below 30 mL/min/1.73 m², according to Endocrine Reviews 25

Monitoring and Safety Considerations

• Vitamin B12 levels should be monitored in patients on metformin for more than 4 years, as approximately 7% develop subnormal levels, as noted in Endocrine Reviews 25

Metformin Management at eGFR 48 mL/min/1.73m²

Introduction to Metformin Management

• At an eGFR of 48 mL/min/1.73m², metformin should be continued at standard doses without mandatory dose reduction, but monitoring frequency should be increased to every 3-6 months and the benefit-risk balance reassessed, particularly in patients with advanced age or concomitant liver disease, as recommended by the American Journal of Kidney Diseases and Kidney International 26, 27

Current Management Algorithm

• eGFR 48 mL/min/1.73m² falls within the safe range (45-59 mL/min/1.73m²) where metformin continuation is explicitly recommended by FDA guidance and major guidelines, such as Kidney International 27

Critical eGFR Thresholds for Future Management

• When eGFR falls to 30-44 mL/min/1.73m², the metformin dose should be reduced by 50% to a maximum of 1000-1250 mg daily, and monitoring frequency increased, as recommended by the American Journal of Kidney Diseases and Kidney International 26, 27
• When eGFR falls below 30 mL/min/1.73m², metformin should be discontinued immediately due to the risk of metformin accumulation and fatal lactic acidosis, as recommended by the American Journal of Kidney Diseases and Kidney International 26, 27

Temporary Discontinuation Scenarios

• Metformin should be held immediately in situations such as acute illness causing volume depletion, hospitalization with elevated risk of acute kidney injury, or before iodinated contrast imaging procedures in patients with history of liver disease, alcoholism, or heart failure, as recommended by Kidney International 27
• eGFR should be re-evaluated 48 hours after contrast procedures before restarting metformin, as recommended by Kidney International 27

Common Pitfalls to Avoid

• Metformin should not be discontinued prematurely at eGFR 48, as this level is well above the threshold requiring discontinuation, as recommended by the American Journal of Kidney Diseases and Kidney International 26, 27

Metformin Management in Patients with Renal Impairment

Introduction to Metformin Management

• The Kidney International guideline recommends calculating the eGFR for patients with renal impairment, as metformin is contraindicated if eGFR falls below 30 mL/min/1.73 m², and the dose must be reduced to a maximum of 1000 mg daily if eGFR is between 30-44 mL/min/1.73 m² 28
• The American Journal of Kidney Diseases guideline states that creatinine-based cutoffs are outdated and have been replaced by eGFR-based thresholds in all current guidelines 29

Management Algorithm Based on eGFR

• For patients with eGFR ≥45 mL/min/1.73 m², the Kidney International guideline recommends continuing metformin 1000 mg daily at the current dose without reduction, and monitoring renal function every 3-6 months 28
• For patients with eGFR 30-44 mL/min/1.73 m², the Kidney International guideline recommends reducing the metformin dose to a maximum of 1000 mg daily, and monitoring renal function every 3-6 months 28
• For patients with eGFR <30 mL/min/1.73 m², the Kidney International guideline recommends discontinuing metformin immediately, as the risk of metformin accumulation and potentially fatal lactic acidosis becomes unacceptably high at this threshold 28

Alternative Therapy if Metformin Must Be Discontinued

• The Kidney International guideline recommends a first-line alternative of GLP-1 receptor agonist (dulaglutide, liraglutide, or semaglutide) with proven cardiovascular and kidney benefits, if metformin must be discontinued due to eGFR <30 mL/min/1.73 m² 28
• The American Journal of Kidney Diseases guideline recommends a second-line alternative of continuing sitagliptin alone at the renally-adjusted dose of 25 mg daily, or switching to linagliptin which requires no dose adjustment at any eGFR level 29

Evidence Supporting Continued Use When Safe

• The American Journal of Kidney Diseases guideline states that population studies demonstrate that metformin use in patients with eGFR 45-60 mL/min/1.73 m² is associated with reduced mortality compared to other glucose-lowering therapies 29

Metformin Management in Patients with Impaired Kidney Function

Introduction to Metformin Dose Adjustment

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend reducing metformin dose to a maximum of 1000 mg daily in patients with a GFR of 30-44 mL/min/1.73 m², due to the increased risk of metformin-associated lactic acidosis (MALA) 30

Monitoring and Dose Adjustment

• The American Diabetes Association (ADA) recommends checking eGFR every 3-6 months in patients with impaired kidney function taking metformin, rather than annually 30
• The FDA suggests monitoring vitamin B12 levels in patients who have been on metformin for more than 4 years, as approximately 7% may develop a deficiency 31

Critical Thresholds for Metformin Use

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines state that metformin must be discontinued immediately if the GFR falls below 30 mL/min/1.73 m², due to the high risk of fatal lactic acidosis 30, 31, 32

Combination Therapy with SGLT2 Inhibitors

• The American Heart Association (AHA) recommends adding an SGLT2 inhibitor (such as canagliflozin or dapagliflozin) to metformin therapy in patients with impaired kidney function, regardless of glucose control, due to the reduced risk of chronic kidney disease progression, heart failure, and cardiovascular events 30, 31, 32

Alternative Therapies when Metformin is Contraindicated

• The American Diabetes Association (ADA) suggests using a GLP-1 receptor agonist (such as dulaglutide, liraglutide, or semaglutide) as a first-line replacement for metformin when the GFR falls below 30 mL/min/1.73 m², due to their documented cardiovascular benefits 32

Metformin Management in Diabetic Patients

Introduction to Metformin Management

• The American Diabetes Association recommends that metformin should not be stopped in diabetic patients with proteinuria if eGFR is ≥60 mL/min/1.73 m², as proteinuria alone is not a contraindication to metformin use 33, 34
• The decision to continue or discontinue metformin is based exclusively on eGFR thresholds, not on the presence of proteinuria, according to the FDA's 2016 revised guidance 33, 34

eGFR-Based Decision Algorithm

• For patients with eGFR ≥60 mL/min/1.73 m², the American College of Clinical Endocrinologists recommends continuing metformin at standard doses (up to 2000-2550 mg daily) regardless of proteinuria status 33, 34
• For patients with eGFR 45-59 mL/min/1.73 m², the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest continuing current metformin dose in most patients, with increased monitoring frequency to every 3-6 months 33, 34
• For patients with eGFR 30-44 mL/min/1.73 m², the American Diabetes Association recommends reducing metformin dose by 50% (maximum 1000 mg daily) and monitoring eGFR every 3-6 months 33, 34
• For patients with eGFR <30 mL/min/1.73 m², the FDA guidance states that metformin should be discontinued immediately, as this is an absolute contraindication 33, 34

Special Considerations

• The FDA and major diabetes/nephrology guidelines (ADA 2023, KDIGO) do not list proteinuria as a contraindication or caution when eGFR is preserved 33, 34
• The American Heart Association recommends temporarily discontinuing metformin during acute illness causing volume depletion, hospitalization with elevated acute kidney injury risk, or iodinated contrast imaging procedures in patients with history of liver disease, alcoholism, or heart failure 33, 34
• The National Kidney Foundation suggests considering adding SGLT2 inhibitors to metformin in patients with proteinuria and eGFR ≥20 mL/min/1.73 m² for additional cardiovascular and renal protection 33, 34

Restarting Metformin After Resolved Acute Kidney Injury

Introduction to Metformin Restart Criteria

• Metformin accumulation during AKI causes metformin-associated lactic acidosis (MALA), which has a high mortality rate, as reported by the American Diabetes Association 35

Pathophysiology and Risks

• Metformin does not cause AKI, but rather AKI impairs metformin clearance, leading to toxic accumulation, according to the European Association for the Study of Diabetes 35

Metformin‑Associated Lactic Acidosis: Risk, Mechanisms, and Management

Incidence and Clinical Risk

• In patients with normal renal and hepatic function, metformin‑related lactic acidosis is exceedingly rare, with an overall incidence of < 10 cases per 100,000 patient‑years and virtually no direct drug‑attributable mortality. 36

• The majority of metformin‑associated lactic acidosis (MALA) episodes arise during acute illnesses that cause acute kidney injury, which reduces metformin clearance; the drug itself is not the primary cause of the injury. 36

Pharmacokinetic Considerations

• Metformin is eliminated unchanged in the urine, making its clearance wholly dependent on renal function. 36

Contraindications and High‑Risk Situations

• An estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² constitutes an absolute contraindication to metformin; therapy must be stopped immediately in this setting. 36

Practical Clinical Guidance

• For typical adults with type 2 diabetes and preserved renal and hepatic function, metformin should be continued because its risk of causing lactic acidosis is minimal. 36

• Appropriate patient selection includes regular eGFR monitoring—at least annually for eGFR ≥ 60 mL/min/1.73 m² and every 3–6 months when eGFR falls below 60. Metformin must be discontinued promptly during acute illnesses or when eGFR declines below 30 mL/min/1.73 m². 36

Comprehensive Metabolic Panel for Metformin Safety and Dizziness Assessment

Metformin Safety Monitoring

• Ordering a comprehensive metabolic panel (CMP) for a 60‑year‑old woman taking metformin 500 mg twice daily who presents with dizziness allows assessment of renal function (eGFR) and hepatic parameters that are essential for safe continuation of metformin. 37
• The CMP includes albumin and total protein, which help evaluate nutritional status and chronic conditions that may contribute to dizziness and influence metformin tolerance. 37

Evaluation of Dizziness in Diabetic Patients on Metformin

• A CMP provides the broader metabolic information needed to investigate dizziness in patients with diabetes on metformin, covering possible hypoglycemia, dehydration, electrolyte disturbances, and renal insufficiency. 37, 38
• Serum glucose measured in the CMP is critical for ruling out hypoglycemia as the cause of dizziness, especially in patients receiving metformin 500 mg twice daily. 37, 38
• The BUN‑to‑creatinine ratio obtained from the CMP can identify prerenal azotemia due to dehydration, which may explain dizziness and warrant temporary discontinuation of metformin. 37

Specific Laboratory Parameters of Clinical Importance

• Serum calcium in the CMP is important because hypercalcemia (corrected calcium > 10 mg/dL) can cause dizziness, fatigue, and altered mental status, and it serves as a predictor of poorer prognosis in certain conditions. 39

Immediate Metformin Discontinuation in Acute Kidney Injury (Evidence from AJKD 2014)

Acute Illnesses Requiring Immediate Metformin Hold

• Metformin should be stopped promptly in patients who develop acute congestive heart failure, because the resulting renal hypoperfusion can precipitate metformin accumulation and increase the risk of lactic acidosis. 40

Concomitant Medications to Discontinue When AKI Occurs (eGFR < 60 mL/min/1.73 m²)

• ACE inhibitors and ARBs should be held during the acute illness to avoid further reductions in glomerular filtration pressure that could worsen metformin clearance. 40
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) should be discontinued because they can impair renal perfusion and exacerbate metformin accumulation. 40
• Aldosterone antagonists should be stopped in the setting of acute kidney injury to prevent additional potassium and volume disturbances that may affect metformin elimination. 40

Metformin Dosing and Safety Recommendations for Patients with eGFR 30–44 mL/min/1.73 m²

Eligibility and Dose Adjustment

• Metformin may be continued when eGFR is 38 mL/min/1.73 m², but the total daily dose should be limited to ≤ 1000 mg and renal function re‑checked every 3–6 months. [41][42]
• For patients whose eGFR falls in the 30–44 mL/min/1.73 m² range, reduce the metformin dose by ≈ 50 % (maximum 1000–1250 mg per day). [41][42]
• Initiation of metformin is not recommended in individuals whose eGFR is 30–44 mL/min/1.73 m² and who are not already receiving the drug. 42
• In the same eGFR range, monitor renal function every 3–6 months to detect further decline. 42
• When eGFR is 30–44 mL/min/1.73 m², clinicians should re‑assess the benefit‑risk balance, especially in older adults, or those with liver disease or heart failure. [41][42]

Monitoring Requirements

• For eGFR 45–59 mL/min/1.73 m², the current metformin dose can be maintained without mandatory reduction, but the monitoring interval should be every 3–6 months. [41][42]
• eGFR < 30 mL/min/1.73 m² is an absolute contraindication; metformin must be stopped immediately. [41][42]
• The 2016 FDA guidance reinforces these thresholds:
  
  • Contraindicated when eGFR < 30 mL/min/1.73 m².
  • Do not initiate when eGFR 30–45 mL/min/1.73 m².
  • Re‑assess benefit‑risk for patients already on metformin within the 30–45 mL/min/1.73 m² range.
  • Continue with monitoring when eGFR 45–60 mL/min/1.73 m². 42
• Vitamin B12 should be checked in patients on metformin for > 4 years, as ≈ 7 % develop deficiency. 41

Safety and Contraindications

• The risk of metformin‑associated lactic acidosis (MALA) rises when eGFR falls below 45 mL/min/1.73 m², particularly if transient drops below 30 mL/min/1.73 m² occur. 41
• Metformin accumulates in renal impairment because it is eliminated unchanged in the urine. 41
• When used according to guidelines, the absolute incidence of lactic acidosis remains very low (< 10 cases per 100 000 patient‑years). 41

Mandatory Temporary Discontinuation

• Hold metformin immediately in any of the following situations, regardless of baseline eGFR 38 mL/min/1.73 m²:
  
  • Acute illness with volume depletion (e.g., sepsis, severe diarrhea, vomiting, dehydration).
  • Hospital admission with a heightened risk of acute kidney injury.
  • Prior to iodinated contrast imaging in patients with a history of liver disease, alcoholism, or heart failure.
  • After contrast exposure, re‑measure eGFR 48 hours later before restarting metformin. 42

Alternative Glucose‑Lowering Therapies

• If metformin must be stopped (e.g., eGFR < 30 mL/min/1.73 m²), GLP‑1 receptor agonists (dulaglutide, liraglutide, semaglutide) are recommended as first‑line agents because of proven cardiovascular and renal benefits. 42
• DPP‑4 inhibitors serve as second‑line options with renal dose adjustments:
  
  • Sitagliptin 25 mg daily for eGFR < 30 mL/min/1.73 m².
  • Linagliptin requires no dose modification. 42
• SGLT2 inhibitors can be added for additional cardiovascular and renal protection when eGFR ≥ 20 mL/min/1.73 m². 42

Additional Clinical Considerations

• Do not rely solely on serum creatinine to guide metformin decisions; always calculate eGFR, as creatinine‑based cutoffs are outdated and may lead to inappropriate discontinuation, especially in elderly or low‑body‑size patients. 42

Metformin Use and Monitoring in Renal Impairment

Dose‑Adjustment Recommendations

Special Population Considerations

Temporary Discontinuation Scenarios

Alternative Therapies When Metformin Is Contraindicated

Monitoring Recommendations

Metformin Management for Contrast‑Enhanced CT Based on eGFR

Pre‑Procedure Assessment

• Verify the patient’s estimated glomerular filtration rate (eGFR) within the 4 weeks preceding a contrast‑enhanced CT when any of the following are present: age > 60 years, a history of renal disease or impairment (dialysis, transplant, single kidney, renal surgery), diabetes mellitus, or hypertension requiring medication. 44, 45, 46, 47

• Use eGFR rather than serum creatinine alone because eGFR is a superior predictor of renal dysfunction and therefore better guides metformin safety decisions. 44, 45, 46, 47

• Define high nephrotoxicity risk for contrast exposure as either serum creatinine > 1.5 mg/dL (≈13 mmol/L) or eGFR < 60 mL/min/1.73 m². 44, 45, 46, 47

eGFR‑Based Metformin Management

Patients with eGFR ≥ 60 mL/min/1.73 m² (Low‑Risk) – No Liver Disease, Alcoholism, Heart Failure, or Intra‑Arterial Contrast

• Discontinue metformin at the moment of contrast administration and hold it for 48 hours after the procedure. 44, 45, 46, 47
• Restart metformin after the 48‑hour hold without a mandatory repeat eGFR assessment, provided the patient has no high‑risk features. 44, 45, 46, 47
• Offer an alternative glucose‑lowering strategy (e.g., short‑acting insulin or other agents) during the 48‑hour hold to prevent hyperglycaemia. 44, 45, 46, 47

Patients with eGFR ≥ 60 mL/min/1.73 m² (Low‑Risk) – Presence of Liver Disease, Alcoholism, Heart Failure, or Intra‑Arterial Contrast

• (Guideline‑based recommendation) Discontinue metformin at contrast administration, hold for 48 hours, and require a repeat eGFR measurement before restarting. (Citation omitted because the specific recommendation is not directly cited; only the general 48‑hour hold is cited above.)

Patients with eGFR 30–60 mL/min/1.73 m² (Moderate Impairment)

• Discontinue metformin at contrast administration, hold for 48 hours, and obtain a repeat eGFR at 48 hours. Restart only if renal function is stable and has not deteriorated. 44, 45, 46, 47

Patients with eGFR < 30 mL/min/1.73 m² (Severe Impairment)

• Metformin is contraindicated; it should be stopped before the procedure and not restarted thereafter. 44, 45, 46, 47

Guideline and Regulatory Evidence

• The U.S. Food and Drug Administration (FDA) drug label and multiple European guidelines uniformly recommend a 48‑hour hold of metformin after iodinated contrast exposure for at‑risk patients (e.g., those with reduced eGFR or comorbidities). This recommendation is considered a strong, class I guideline with high‑level (A) evidence supporting the precaution against metformin‑associated lactic acidosis. 44, 45, 46, 47

eGFR‑Based Metformin Dosing and Monitoring in Chronic Kidney Disease

Dosing Recommendations

• Standard metformin dosing (up to 2000–2550 mg daily) is appropriate when estimated GFR (eGFR) is ≥ 60 mL/min/1.73 m²; no dose reduction is required. 48, 49
• When eGFR is 45–59 mL/min/1.73 m², most patients can continue their current metformin dose without mandatory reduction. 48, 49
• If eGFR falls to 30–44 mL/min/1.73 m², the metformin dose should be reduced by ≈ 50 % (maximum 1000 mg per day). 48, 49
• Metformin must be discontinued immediately when eGFR is < 30 mL/min/1.73 m² (absolute contraindication). 48, 49

Monitoring Requirements

• Check eGFR at least annually for patients with eGFR ≥ 60 mL/min/1.73 m². 48, 49
• Increase eGFR monitoring frequency to every 3–6 months once eGFR drops below 60 mL/min/1.73 m². 48, 49
• For patients on metformin for > 4 years, assess vitamin B12 levels; approximately 7 % develop deficiency. 48

Guideline Consensus and Evidence Strength

• The 2022 KDIGO guideline and the 2022 ADA/KDIGO consensus report (both high‑quality, recent evidence) recommend metformin use when eGFR ≥ 30 mL/min/1.73 m² (class 1, level B). 48, 49
• Both guidelines advise a 50 % dose reduction for eGFR 30–44 mL/min/1.73 m² (class 1, level B). 48, 49
• Both guidelines state that metformin is contraindicated when eGFR < 30 mL/min/1.73 m² (class 1, level B). 48, 49

Alternative Glucose‑Lowering Therapies When Metformin Is Contraindicated

• GLP‑1 receptor agonists with proven cardiovascular benefit are preferred first‑line alternatives in patients with eGFR < 30 mL/min/1.73 m².

  • Dulaglutide 0.75–1.5 mg weekly can be used down to eGFR > 15 mL/min/1.73 m² without dose adjustment. 48
  • Liraglutide 1.2–1.8 mg daily may be used, though data are limited in severe CKD. 48
  • Semaglutide 0.5–1 mg weekly may be used, with limited data for severe CKD. 48

• If a DPP‑4 inhibitor is chosen, sitagliptin should be reduced to 25 mg daily when eGFR < 30 mL/min/1.73 m², whereas linagliptin requires no renal dose adjustment. (cited in the same KDIGO/ADA consensus) 48, 49

All facts are derived from KDIGO and ADA/KDIGO consensus statements (2022) with the indicated evidence grading.

Metformin Initiation and Management in Patients with eGFR ≈ 67 mL/min/1.73 m²

Eligibility and Recommended Dosing

• Patients with an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m² can start standard metformin therapy up to 2 000–2 550 mg daily without any dose reduction, and it can be safely combined with linagliptin (no dose adjustment required) 50.
• The KDIGO 2020 guideline advises that adults with type 2 diabetes and chronic kidney disease (CKD) whose eGFR is ≥ 30 mL/min/1.73 m² should receive metformin (Grade 1B recommendation) 50.

Monitoring Frequency

• For eGFR values between 60–89 mL/min/1.73 m² (CKD stage 2), renal and metabolic monitoring should be performed every 3–6 months rather than annually 50.
• KDIGO specifically recommends increasing monitoring frequency when eGFR falls below 60 mL/min/1.73 m² 50.

Future Renal Thresholds and Dose Adjustments

Situations Requiring Temporary Metformin Hold

• Acute illnesses that cause volume depletion (e.g., sepsis, severe diarrhea, vomiting, dehydration) should prompt temporary discontinuation of metformin 50.
• Hospital admission with an elevated risk of acute kidney injury warrants holding metformin until renal function stabilizes 50.

All statements are derived from KDIGO 2020 recommendations and the cited Kidney International source (Grade 1B evidence where specified).

Metformin Dose Adjustment in Renal Impairment

Dose‑Adjustment Algorithm Based on eGFR

• In patients with an estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m², the standard metformin regimen of 850 mg every 8 hours (total 2550 mg/day) must be reduced; when eGFR is 30–44 mL/min/1.73 m² the dose should be cut by 50 % (maximum ≈ 1000 mg/day, e.g., 500 mg twice daily)【51】.
• When eGFR ≥ 60 mL/min/1.73 m², the current dose can be continued without change, with renal function checked at least annually【51】.
• For eGFR 45–59 mL/min/1.73 m², dose reduction should be considered in older adults or those with concurrent liver disease; most patients may remain on the current dose but require more frequent renal monitoring (every 3–6 months)【51】.
• In the eGFR 30–44 mL/min/1.73 m² range, the dose must be reduced to a maximum of 1000 mg/day (e.g., 500 mg twice daily) and renal function re‑checked every 3–6 months, with a careful benefit‑risk reassessment in frail or comorbid patients【51】.
• When eGFR falls below 30 mL/min/1.73 m², metformin must be stopped immediately because the risk of lactic acidosis becomes unacceptably high【51】.

Situations Requiring Temporary Metformin Suspension

• Metformin should be held temporarily during any acute condition that causes volume depletion (e.g., severe infection, diarrhea, vomiting, dehydration)【51】.
• Hold the drug during hospitalizations with a high risk of acute kidney injury【51】.
• Suspend before iodinated‑contrast procedures in patients with a history of liver disease, alcoholism, or heart failure; re‑measure eGFR 48 hours after the procedure before restarting【51】.

Monitoring Requirements

• Vitamin B12 levels should be checked in patients who have been on metformin for more than 4 years, as roughly 7 % develop deficiency【51】.
• Renal function should be monitored every 3–6 months in any patient whose eGFR is < 60 mL/min/1.73 m²【51】.

Alternative Therapies When Metformin Is Discontinued

• First‑line alternatives: GLP‑1 receptor agonists (e.g., dulaglutide, liraglutide, semaglutide) provide documented cardiovascular benefits; dulaglutide can be used without dose adjustment down to eGFR > 15 mL/min/1.73 m²【51】.
• Second‑line alternatives: DPP‑4 inhibitors with appropriate renal dosing—sitagliptin 25 mg daily is acceptable when eGFR < 30 mL/min/1.73 m², and linagliptin requires no dose adjustment【51】.

Common Pitfalls to Avoid

• Do not rely solely on serum creatinine; always calculate eGFR, especially in elderly or short‑stature patients【51】.
• Do not discontinue metformin prematurely when eGFR is 45–59 mL/min/1.73 m², as this range is well above the threshold for absolute cessation【51】.
• Adjust the dose proportionally as eGFR declines; failure to do so increases the risk of drug accumulation and adverse events【51】.

Safety Evidence

• Observational population data indicate that metformin use in patients with eGFR 45–60 mL/min/1.73 m² is associated with reduced mortality compared with other glucose‑lowering agents【51】.
• When prescribed according to guideline‑based dosing, the incidence of metformin‑associated lactic acidosis remains very low (< 10 cases per 100 000 patient‑years)【51】.

Metformin Management During Acute Illness and Vitamin B12 Monitoring

Acute‑Illness “Sick‑Day” Management

• Discontinue metformin immediately in patients who develop severe hyperglycemia with ketonuria, dehydration, infection, myocardial infarction, stroke, or any acute condition that could impair renal or hepatic function – this prevents accumulation and lactic acidosis risk. 52
• Hold metformin during any acute volume‑depletion state (e.g., sepsis, severe infection, marked dehydration, severe diarrhea, vomiting) because these conditions markedly reduce metformin clearance and increase the risk of lactic acidosis. 52

Vitamin B12 Surveillance

• Screen for vitamin B12 deficiency in patients on metformin for more than four years, especially when anemia or peripheral neuropathy is present; approximately 7 % develop deficiency over this period. 52
• Provide periodic vitamin B12 supplementation when laboratory levels are low to mitigate deficiency‑related complications. 52

Metformin Extended‑Release Guidance for Older Adults with Preserved Renal Function

Timing of Administration

• The American Diabetes Association (ADA) recommends that, in patients aged ≥ 65 years with an estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m², metformin extended‑release should be taken with the evening meal rather than at bedtime; the current dose may be continued with renal monitoring every 3–6 months. Evidence level: Moderate 53

Renal Function–Based Dosing

• eGFR ≥ 60 mL/min/1.73 m²: Continue standard metformin dosing (up to 2000 mg daily) and perform annual renal monitoring. Evidence level: Moderate 53
• eGFR 45–59 mL/min/1.73 m²: Maintain the existing dose in most patients; consider dose reduction in those with advanced age, liver disease, or heart failure, and monitor renal function every 3–6 months. Evidence level: Moderate 53
• eGFR 30–44 mL/min/1.73 m²: Reduce the dose by ≈ 50 % (maximum 1000 mg daily) and monitor renal function every 3–6 months. Evidence level: Moderate 53
• eGFR < 30 mL/min/1.73 m²: Discontinue metformin immediately (absolute contraindication). Evidence level: Moderate 53

eGFR‑Based Management Algorithm

Special Considerations in Older Adults

• Older adults exhibit heightened susceptibility to metformin‑related gastrointestinal intolerance, reduced appetite, and dehydration, even when eGFR is preserved. Evidence level: Moderate 54
• Metformin‑induced gastrointestinal side effects and appetite suppression may be especially problematic in this population, warranting closer clinical observation. Evidence level: Moderate 54
• Temporary discontinuation of metformin is advised during acute illnesses, hospitalizations, or procedures that could impair renal function, to mitigate the risk of lactic acidosis. Evidence level: Moderate 54

Metformin Renal Safety and Monitoring

Lack of Nephrotoxicity

• Metformin does not cause or worsen kidney injury; any renal impairment reduces drug clearance, leading to accumulation, but the medication itself is not nephrotoxic. 55

Pharmacokinetic Relationship with Renal Function

• Metformin is eliminated unchanged in the urine, so reduced eGFR impairs clearance and raises the risk of drug accumulation and lactic acidosis, although the drug does not directly damage the kidneys. 55

Guideline and Regulatory Statements

American Diabetes Association (ADA)

• The ADA notes that metformin’s main adverse effects are gastrointestinal (e.g., bloating, diarrhea) and that lactic acidosis is now recognized as a very rare event. 55

U.S. Food and Drug Administration (FDA)

• In 2016 the FDA updated metformin labeling to permit use in patients with an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m², replacing older creatinine‑based restrictions. 55

Long‑Term Monitoring

• Approximately 7 % of patients receiving metformin for more than four years develop vitamin B12 deficiency, which can exacerbate neuropathy; periodic B12 testing is therefore recommended. 55

Metformin Management in Stable Congestive Heart Failure

Eligibility and Safety

• Metformin can be continued in patients with type 2 diabetes who have stable, compensated congestive heart failure and an estimated glomerular filtration rate (eGFR) > 30 mL/min/1.73 m²; it should be avoided in unstable or hospitalized heart‑failure patients. (American Diabetes Association 2023 guideline) 56

• In stable, compensated heart failure with preserved renal function (eGFR > 30 mL/min/1.73 m²), the risk of metformin‑associated lactic acidosis is minimal when the drug is dosed according to renal function. (Annals of Internal Medicine 2018; Diabetes Care 2018; ADA 2023) [57][58]56

Renal‑Function–Based Dosing Algorithm

Guideline Recommendations

• The 2023 American Diabetes Association guideline explicitly states that metformin is appropriate for stable heart‑failure patients but must be avoided in unstable or hospitalized congestive heart‑failure scenarios. (Class I recommendation) 56

Situations Requiring Immediate Temporary Discontinuation

• Acute decompensated heart failure with hypoperfusion, hypoxemia, or hemodynamic instability. (ADA 2023) 56
• Hospital admission for any acute illness that could impair renal or hepatic function. (ADA 2023) 56
• Volume‑depletion states (e.g., sepsis, severe infection, diarrhea, vomiting, dehydration). (ADA 2023) 56
• Planned iodinated‑contrast imaging in patients with eGFR 30–60 mL/min/1.73 m², liver disease, alcoholism, or heart failure – hold metformin at the time of the procedure and reassess eGFR 48 hours later before restarting. (ADA 2023) 56

Monitoring Requirements

• Renal function: Check eGFR every 3–6 months once it falls below 60 mL/min/1.73 m². (ADA 2023) 56
• Vitamin B12: Screen for deficiency after ≥ 4 years of metformin therapy; ≈ 7 % develop deficiency. (Kidney International 2020) 59

Evidence of Mortality Benefit in Stable Heart Failure

• Observational cohort data show that, among patients with eGFR 45–60 mL/min/1.73 m², metformin use is associated with lower all‑cause mortality compared with other glucose‑lowering agents. (Kidney International 2020; observational evidence, moderate strength) 59

Alternative Glucose‑Lowering Therapies When Metformin Is Contraindicated

• First‑line: Sodium‑glucose cotransporter‑2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, canagliflozin) are recommended for heart‑failure patients (both preserved and reduced ejection fraction) to reduce worsening heart failure and cardiovascular death. (ADA 2023) 56
• Second‑line: Glucagon‑like peptide‑1 (GLP‑1) receptor agonists (dulaglutide, liraglutide, semaglutide) provide documented cardiovascular benefit. (ADA 2023; Kidney International 2020) [56][59]
• Third‑line: Dipeptidyl peptidase‑4 (DPP‑4) inhibitors with renal dose adjustment (e.g., sitagliptin 25 mg daily when eGFR < 30 mL/min/1.73 m²; linagliptin requires no adjustment). (Kidney International 2020) 59

eGFR‑Based Metformin Management for Coronary Angiography

Patients with eGFR ≥ 60 mL/min/1.73 m² (normal to mild renal impairment)

• The American Diabetes Association (2023) states that metformin may be continued through coronary angiography without interruption when eGFR is ≥ 60 mL/min/1.73 m² and no additional risk factors (e.g., liver disease, heart failure, alcoholism, or intra‑arterial contrast) are present. 60

Patients with eGFR 30–60 mL/min/1.73 m² (moderate renal impairment)

• The FDA‑endorsed guidance recommends discontinuing metformin at the moment iodinated contrast is administered and holding the drug for 48 hours after the procedure. 60
• A mandatory re‑evaluation of eGFR is required at 48 hours before restarting metformin to confirm that renal function has not worsened. 60
• This precaution is especially important when the patient has co‑existing liver disease, alcohol use disorder, heart failure, or will receive intra‑arterial contrast during the angiography. 60

Patients with eGFR < 30 mL/min/1.73 m² (severe renal impairment)

• Metformin is absolutely contraindicated; it must be stopped before the procedure and should not be restarted thereafter. 60

Guideline Consensus, Regulatory Guidance, and Strength of Evidence

• The 2016 FDA drug‑label update replaced creatinine‑based cutoffs with eGFR thresholds for metformin use, establishing the current eGFR‑based algorithm. 60
• The FDA, the American Diabetes Association (2023), and the KDIGO (2022) consensus all issue a Class I recommendation—supported by high‑level evidence—for a 48‑hour metformin hold in patients at risk (eGFR 30–60 mL/min/1.73 m² or presence of additional risk factors) undergoing iodinated contrast procedures. 60

Metformin Prescribing Recommendations for Chronic Kidney Disease Stage 3

eGFR 45–59 mL/min/1.73 m² (CKD Stage 3a)

• The American Diabetes Association (2023) and the FDA (2016) endorse initiating or continuing metformin at standard daily doses (up to ≈2 g‑2.5 g) in patients with eGFR 45–59 mL/min/1.73 m², without mandatory dose reduction – a strong recommendation. 61
• Monitoring of renal function should be performed every 3–6 months (instead of annually) to detect any decline in eGFR – a strong recommendation. 61
• The FDA 2016 label explicitly permits metformin use in this eGFR range, confirming regulatory support. 61

eGFR 30–44 mL/min/1.73 m² (CKD Stage 3b)

• For patients already receiving metformin, the dose should be reduced by 50 % to a maximum of ≈1 g daily – a strong recommendation. 61
• New initiation of metformin is not recommended in individuals whose eGFR is 30–44 mL/min/1.73 m² and who are not already on the drug – a strong recommendation. 61
• Clinicians should re‑assess the benefit‑risk balance carefully in frail or highly comorbid patients before continuing therapy – a moderate recommendation. 61
• Renal function should be re‑checked every 3–6 months while on metformin in this eGFR range – a strong recommendation. 61

eGFR < 30 mL/min/1.73 m² (Absolute Contraindication)

• Metformin must be discontinued immediately when eGFR falls below 30 mL/min/1.73 m² – an absolute contraindication per FDA labeling. 61

Safety and Outcome Evidence

• Observational population studies cited by the American Diabetes Association show that metformin use in patients with eGFR 45–60 mL/min/1.73 m² is associated with reduced mortality compared with other glucose‑lowering agents – moderate‑quality evidence. 61
• The incidence of metformin‑associated lactic acidosis remains very low (<10 cases per 100 000 patient‑years) when prescribing follows eGFR‑based guidelines – moderate‑quality evidence. 61

Additional Monitoring Requirements

• Vitamin B12 levels should be screened in patients on metformin for more than 4 years, as ≈7 % develop deficiency – a moderate recommendation. 61
• eGFR, not serum creatinine alone, should guide dosing decisions; creatinine‑based cutoffs are outdated and may lead to inappropriate discontinuation, especially in older or small‑statured individuals – a strong recommendation. 61

Temporary Discontinuation Scenarios (Regardless of Baseline eGFR)

• Metformin should be held immediately during acute illnesses that cause volume depletion (e.g., sepsis, severe diarrhea, vomiting, dehydration).
• Hold metformin during hospital admission with high risk of acute kidney injury or acute decompensated heart failure with hypoperfusion.
• Prior to iodinated contrast imaging in patients with eGFR 30–60 mL/min/1.73 m² who also have liver disease, alcoholism, heart failure, or receive intra‑arterial contrast, metformin must be stopped and eGFR re‑measured 48 hours after the procedure before restarting – a strong recommendation. 61

Alternative Therapies When Metformin Must Be Discontinued

• First‑line alternatives (eGFR < 30):** GLP‑1 receptor agonists (e.g., dulaglutide, liraglutide, semaglutide) are preferred for their documented cardiovascular and renal benefits; dulaglutide can be used down to eGFR > 15 mL/min/1.73 m² without dose adjustment – a strong recommendation**. 61
• Second‑line alternatives: DPP‑4 inhibitors with renal dose adjustments (e.g., sitagliptin 25 mg daily at eGFR < 30; linagliptin requires no adjustment at any eGFR) – a moderate recommendation. 61
• Combination therapy in CKD Stage 3: Adding an SGLT2 inhibitor to metformin (when eGFR ≥ 20 mL/min/1.73 m²) provides additional cardiovascular and renal protection independent of glucose lowering, reducing CKD progression, heart failure, and cardiovascular death – a strong recommendation. 61

Common Prescribing Pitfalls to Avoid

• Do not discontinue metformin prematurely at eGFR 45–59 mL/min/1.73 m²; this range is safely above the cessation threshold. 61
• Increase monitoring frequency to every 3–6 months once eGFR drops below 60 mL/min/1.73 m²; annual checks are insufficient. 61
• Do not initiate metformin in patients with eGFR 30–44 mL/min/1.73 m² who are not already on therapy. 61

Metformin Use in Patients with Moderate Chronic Kidney Disease (eGFR 45–59 mL/min/1.73 m²)

Eligibility and Dosing

• The FDA and major diabetes/nephrology guidelines state that metformin may be continued without mandatory dose reduction in individuals with eGFR 45–59 mL/min/1.73 m² (CKD stage 3a); standard daily doses up to 2000–2550 mg remain appropriate. 62

Monitoring Requirements

• eGFR should be re‑checked every 3–6 months when kidney function is below 60 mL/min/1.73 m². 62
• Vitamin B12 levels ought to be monitored in patients who have used metformin for more than 4 years, because roughly 7 % develop a deficiency. 62

Dose Adjustments by eGFR

These dosing thresholds are derived from the 2016 FDA label revision that replaced creatinine‑based cutoffs with eGFR‑based thresholds for metformin safety. 62

Situations Requiring Temporary Metformin Hold

• Acute illnesses causing volume depletion (e.g., sepsis, severe diarrhea, vomiting, dehydration, fever).
• Hospitalization with an elevated risk of acute kidney injury.
• Acute decompensated heart failure with hypoperfusion or hypoxemia.
• Prior to iodinated contrast procedures in patients with liver disease, alcoholism, heart failure, or when intra‑arterial contrast will be used; metformin should be held at the time of the procedure and eGFR re‑checked 48 hours later before restarting. 62

Alternative Glucose‑Lowering Therapies When Metformin Must Be Discontinued

• GLP‑1 receptor agonists (e.g., dulaglutide, liraglutide, semaglutide) are first‑line alternatives; dulaglutide can be used down to eGFR > 15 mL/min/1.73 m² without dose adjustment. 62
• DPP‑4 inhibitors with renal dose adjustment: sitagliptin 25 mg daily at eGFR < 30 mL/min/1.73 m²; linagliptin requires no adjustment. 62
• SGLT2 inhibitors may be added when eGFR ≥ 20 mL/min/1.73 m² for additional cardiovascular and renal protection independent of glycemic effect. 62